Harmony Biosciences Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
Harmony Biosciences Holdings, Inc. filed this Form 8-K on August 2, 2022, under Items 2.02, 7.01, and 9.01. The filing announces financial results for the quarter ended June 30, 2022, and furnishes an investor presentation. The company is listed on Nasdaq under the symbol HRMY.
Financial Results and Key Metrics
The filing states that the company issued a press release reporting quarterly financial results, but the press release text and underlying financial figures are not included in the provided filing content. Accordingly, revenue, profit or loss, cash flow, margins, debt, liquidity, and other financial metrics are not clearly available from this text.
Changes Versus Prior Comparable Period
The filing does not provide the comparative financial results or quantify changes from the prior-year quarter or prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- An investor presentation dated August 2, 2022 was posted to the company’s investor-relations website and furnished as Exhibit 99.2.
- The investor presentation may be used in discussions with investors, analysts, and others. It contains forward-looking statements and is subject to the risks described in the company’s filings, including its 2021 Form 10-K.
- Management states that forward-looking statements are based on current expectations, assumptions, plans, and projections and may differ materially from actual results.
- The company disclaims any obligation to update forward-looking statements, except as required by law.
- The furnished press release and investor presentation are not deemed filed for purposes of Section 18 of the Exchange Act, except where specifically incorporated by reference.
Facts Investors Should Verify
- Review Exhibit 99.1 for the actual second-quarter 2022 revenue, earnings, cash flow, balance-sheet, and operating results.
- Review Exhibit 99.2 for management’s outlook, product and commercial updates, and any financial guidance.
- Compare the reported quarter with the second quarter of 2021 and the immediately preceding quarter.
- Assess the risk factors in the 2021 Form 10-K and subsequent SEC filings before relying on forward-looking statements.